How can we utilize local excision to help, not harm, geriatric patients with rectal cancer?

Publication date: Available online 14 December 2019Source: European Journal of Surgical OncologyAuthor(s): Shruti Sevak, Tine Gregoir, Albert Wolthuis, Matthew AlbertAbstractA majority of the morbidity and mortality burden of rectal cancer is distributed within the geriatric age group. Current surgical and medical treatment modalities pose significant challenges in treating complications specifically in the already pre-disposed senior population with baseline dysfunction. This chapter reviews the work-up, management, current data and oncologic outcomes of treating rectal cancer in the senior adult.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research

Related Links:

ConclusionsBoth serum and tissue CEA were significant factors for predicting good tumor response following preoperative CRT. However, tissue CEA was not associated with the oncologic outcome. The possibility of radiologic resistance of high CEA tumors is expected to be investigated through further studies.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: April 2020Source: Biomedicine &Pharmacotherapy, Volume 124Author(s): Wei Qu, Wenzhong Huang, Fang Yang, Hui Ju, Guanghui ZhuAbstractOn account of the acquired drug resistance, the potency of cisplatin-based chemotherapy is far from satisfactory in rectal cancer. Increasing evidence has highlighted the crucial function of aberrantly expressed lncRNAs on the cisplatin resistance in multiple cancers. This research was the first attempt to decipher the underlying function and mechanism of long intergenic non-protein coding RNA 461 (LINC00461) in rectal cancer and also its relation to cisplatin resistance ...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Preoperative chemoradiotherapy is the recommended standard of care for patients with local advanced rectal cancer. However, it remains unclear, whether a prolonged time interval to surgery results in an increa...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Conditions:   Rectal Cancer;   Radiotherapy;   Immunotherapy Intervention:   Drug: Camrelizumab Sponsor:   Wuhan Union Hospital, China Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionsAvailable data do not support the hypothesis of an association of DPP4i treatment with malignancies, with a possible beneficial effect for colon-rectal cancer.
Source: Acta Diabetologica - Category: Endocrinology Source Type: research
Authors: Park YY, Lee KY, Kim NK, Lee SB, Kim GR, Min BS, Oh ST Abstract PURPOSE: Adjuvant chemotherapy (aCT) in rectal cancer patients who have undergone curative resection after neoadjuvant chemoradiation (nCRT) is controversial. We aimed to investigate the benefits of using aCT and the clinical impact of completing aCT in ypstage 2 rectal cancer patients. METHODS: We retrospectively reviewed clinicopathological data from patients who had undergone radical resection after nCRT between January 2006 and December 2012. In total, 152 patients with ypT3/4N0M0 rectal cancer were included. Of these patients, 139 ini...
Source: Annals of Coloproctology - Category: Gastroenterology Tags: Ann Coloproctol Source Type: research
Conclusions: High MRE11 expression is an independent prognostic marker in LSCRC and enhanced prognostic potency of combining high MRE11 with high TIICs in LSCRC, mainly due to differential immune signaling activated by MRE11 in RSCC and LSCRC, respectively.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In the 1990s preoperative radiotherapy and chemoradiation (CRT) were administered in a range of tumours with the aim of reducing tumour volumes to enhance operability prior to definitive surgical intervention. Attempts to show a distinction between responders and non-responders by grading the pathological effects of preoperative CRT treatment originated with Mandard with a model proposed in oesophageal cancer[1]. Using an arbitrary scale to describe the balance between residual fibrosis and residual viable tumour, the authors categorised the degree of pathological tumour regression into 5 grades.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Controversy Source Type: research
Conditions:   Rectal Cancer;   Radiotherapy;   Immunotherapy Intervention:   Drug: Camrelizumab Sponsor:   Wuhan Union Hospital, China Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Li C, Zuo D, Liu T, Yin L, Li C, Wang L Abstract Objective: To assess the association between MUC expression levels in colorectal cancer (CRC) tissues and prognosis and investigate the associations between MUC expression levels and CRC clinicopathological characteristics. Methods: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched from inception through September 13, 2019, to identify studies investigating the association between MUC expression levels in CRC tissues and prognosis. Pooled hazard ratios (HRs) or odds ratio (ORs) with 95% confidence intervals (CIs) were used ...
Source: Gastroenterology Research and Practice - Category: Gastroenterology Tags: Gastroenterol Res Pract Source Type: research
More News: Cancer | Cancer & Oncology | Geriatrics | Rectal Cancers | Surgery